In this context, our study revealed a mechanistic crosstalk among an onco-splicing factor, alternative splicing event of lncRNA and tumorigenesis of melanoma stem cells, enabling PTBP1 and the splicing of LHFPL3-AS1 to serve as the attractive therapeutic targets for melanoma. The gene discussed is PTBP1; the disease is melanoma.